PHILIPPE PETRUS: Open Payments
NPI 1639398035 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,230 in 55 payments from 11 companies in 2025. Trend: 2023 $1,315 · 2024 $1,055 · 2025 $1,230
Food & beverage: $1,230
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $375 |
| Neurocrine BioSciences, Inc. | 7 | $180 |
| E.R. Squibb & Sons, L.L.C. | 7 | $149 |
| Sage Therapeutics, LLC | 2 | $113 |
| Janssen Pharmaceuticals, Inc | 5 | $102 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Vanda Pharmaceuticals Inc. | 4 | $65 |
| Alkermes, Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| ABBVIE INC. | 2 | $42 |
Products named: CAPLYTA, INGREZZA, COBENFY, ZURZUVAE, INVEGA SUSTENNA, REXULTI, FANAPT, UZEDY.
Industry payments across TX — which companies pay providers there.
